Myeloperoxidase-derived oxidants damage artery wall proteins in an animal model of chronic kidney disease–accelerated atherosclerosis
Open Access
- 1 May 2018
- journal article
- research article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 293 (19) , 7238-7249
Abstract
No abstract availableKeywords
Funding Information
- HHS NIH National Heart, Lung, and Blood Institute (NHLBI) (K08HL130944)
- HHS NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (P30DK081943, P30DK089503)
- Renal Research Institute (2015)
This publication has 99 references indexed in Scilit:
- Endothelial Dysfunction in the Apolipoprotein E-deficient Mouse: insights into the influence of diet, gender and agingLipids in Health and Disease, 2011
- Quantitative Analysis of Amino Acid Oxidation Markers by Tandem Mass Spectrometry2011
- Myeloperoxidase in Chronic Kidney DiseaseIndian Journal of Clinical Biochemistry, 2010
- Associations between the CYBA 242C/T and the MPO –463G/A Polymorphisms, Oxidative Stress and Cardiovascular Disease in Chronic Kidney Disease PatientsBlood Purification, 2007
- The human myeloperoxidase gene is regulated by LXR and PPARα ligandsBiochemical and Biophysical Research Communications, 2006
- Statins downregulate myeloperoxidase gene expression in macrophagesBiochemical and Biophysical Research Communications, 2005
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004
- Kidney Disease as a Risk Factor for Development of Cardiovascular DiseaseHypertension, 2003
- Atherosclerotic cardiovascular disease risks in chronic hemodialysis patientsKidney International, 2000
- Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions.Journal of Clinical Investigation, 1994